Revenue Growth and Profitable Third Quarter
23 February 2024
Revenue Growth and Profitable Third Quarter
For the third quarter ending 31 Dec 2023, Blis Technologies Limited (Blis) delivered revenue growth
of 10% on the same period last year and a positive EBITDA result of $0.3m (unaudited).
Revenue growth came from a 12% increase in B2B revenue and a stronger than expected result for
New Zealand and Amazon.
“Momentum continues to build around the successful execution of the refocused strategic plan. This
has involved amongst other activities, working closely with business partners to sell more Blis
product profitably into B2C and B2B channels.” said Scott Johnson, CEO.
Based on the latest customer sales forecasts and market feedback, guidance is for full year revenue
to be about $11.0m, with EBITDA in the range of breakeven to $0.3m. This marks a return to
profitability for the company.
Ends
For further information, please contact:
Scott Johnson
CEO
+64 21 488 831
About Blis Technologies Ltd
Delivering proven health benefits through evidence-based, advanced probiotics
Blis Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut.
Combining innovation with evidence-based research and the highest quality production controls enables
the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath),
immune support, teeth and gum health and skin health. BLIS® products are sold throughout New Zealand
and in Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at
www.blis.co.nz.
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- BGP — Briscoe Group Limited: Full Year Results to 28 January 20242024-03-12
“Results announcement Results for announcement to the market Name of issuer BRISCOE GROUP LIMITED Reporting Period Full Year (52 weeks) – 30 January 2023 to 28 January 2024 Previous Reporting Period Full Year (52 weeks) – 31 January 2022 to 29 January 2023 Currency…”
- PEB — Pacific Edge Limited: Cash Burn Slows; Coverage Catalysts in Focus2024-05-20
“5 Cxbladder tests; and the continued advancement of our clinical evidence program, which will give us multiple opportunities to seek a Medicare coverage reconsideration,” Dr Meintjes said. “Meanwhile, we see several catalysts to the company accelerating the adoption of Cxb…”
- AFT — AFT Pharmaceuticals Limited: AFT reports record revenue and earnings2024-05-22
“Intercompany transactions, balances and unrealised gains on transactions between subsidiary companies are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Critical accounting estimates and j…”